Cognitive Disorders
2
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Allergy TherapeuticsUK - West Sussex
1 programHIV Levels in Cerebrospinal Fluid and Brain Function in Patients Receiving Anti-HIV DrugsN/A1 trial
Active Trials
NCT00001103Completed
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AbbVieSDI-118
GSKGSK1034702
IpsenEGb761®
Clinical Trials (4)
Total enrollment: 90 patients across 4 trials
A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect
Start: Mar 2019Est. completion: Mar 202032 patients
Phase 1Completed
Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study
Start: Jul 2009Est. completion: Aug 20094 patients
Phase 1Completed
NCT00001103Allergy TherapeuticsHIV Levels in Cerebrospinal Fluid and Brain Function in Patients Receiving Anti-HIV Drugs
HIV Levels in Cerebrospinal Fluid and Brain Function in Patients Receiving Anti-HIV Drugs
N/ACompleted
EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders
Start: Jun 2014Est. completion: Apr 201554 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space